Search clinical trials for: PegIFNα-2a (P)

Total 6826 results

National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

Taiwan
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical...

Completed

SR-BI and Antiviral Treatment Response in HCV

Chronic Hepatitis C
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Hepatitis B, Chronic

New Zealand
PharmaEssentia

Completed

Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects

Healthy Volunteers

Canada
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Hepatitis B, Chronic

Taiwan
Gilead Sciences

Completed

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Hepatitis C, Chronic

United States, Puerto Rico, Australia
Joke Wuyts
Association of Belgian Pharmacies (APB)

Completed

Studying the Impact of a Medication Use Evaluation by the Community Pharmacist (SIMENON)

Aging
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)

Hepatitis B, Chronic

China
Hoffmann-La Roche

Completed

A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Israel
Vertex Pharmaceuticals Incorporated
ViroChem Pharma

Completed

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Hepatitis C

Canada, United States, Argentina, Puerto Rico
Tibotec BVBA

Completed

A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

Hepatitis C, Chronic

France, United Kingdom, Sweden
Hoffmann-La Roche

Completed

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Hepatitis C, Chronic

Brazil
Hoffmann-La Roche

Completed

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

Hepatitis C, Chronic

Australia, France, Italy, Spain, United States, Canada, Germany, Puerto Rico, New Zealand
Hoffmann-La Roche

Completed

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

United States, Spain, France, Canada, Germany, Austria, Australia, Brazil, United Kingdom, Italy, Mexico, Poland, Puerto Rico
Bristol-Myers Squibb

Completed

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy (STRUCTURE)

Hepatitis C

France, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Taiwan, United Kingdom, United States, Spain, Israel, Argentina, Poland
Abbott Medical Devices

Completed

ENHANCE-Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction (ENHANCE)

Bradycardia

Thailand, China, Australia, India, Italy
Fisher and Paykel Healthcare

Completed

The Evaluation of a Mask Seal/Mask for the Treatment of Obstructive Sleep Apnea (OSA)

Obstructive Sleep Apnea | Sleep Disordered Breathing

New Zealand
Coloplast A/S

Completed

Evaluation of the Peel Force of New Adhesives From the Skin

Stoma Ileostomy

Denmark
University of Nebraska

Terminated

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

Chronic Hepatitis C | Relapse | Genotype 1

United States
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

Hepatitis C, Chronic

United States, Puerto Rico
Brooke Army Medical Center
Hoffmann-La Roche; The Geneva Foundation

Completed

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus (HCVNASH)

Hepatitis C | Fatty Liver

United States
Sheba Medical Center

Unknown

Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.

Chronic Hepatitis C
University of Maryland, Baltimore
PATH

Terminated

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa

Shigella

United States
H. Lee Moffitt Cancer Center and Research Institute
San Diego State University; University of Minnesota; University of Arizona

Completed

Emotional Support Messages Following a Cancer Diagnosis

Anxiety | Psychological Stress

United States
Hoffmann-La Roche

Completed

Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

Myelogenous Leukemia, Chronic

Germany
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B

Hepatitis B, Chronic

Estonia, Lithuania, Latvia
HepNet Study House, German Liverfoundation
Gilead Sciences; Hannover Medical School; Hoffmann-La Roche

Completed

HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis (HIDIT-II)

Hepatitis D

Germany, Greece, Romania
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Hepatitis C

United States, Canada, Germany, Puerto Rico, Spain
Hoffmann-La Roche

Completed

ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B

Hepatitis B, Chronic

Turkey
Hoffmann-La Roche

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Hepatitis C, Chronic

United States
Daewoong Pharmaceutical Co. LTD.

Not yet recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia

Hypertension | Hyperlipidemias
Zealand University Hospital
University of Copenhagen

Recruiting

Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression (IPOS)

Colon Cancer

Denmark
Hoffmann-La Roche

Terminated

Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)

HIV/HCV Coinfection

Belgium
University Health Network, Toronto

Unknown

Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy

Hepatitis B | Hepatitis C

Canada
Sonova AG
Hearts for Hearing

Completed

Optimizing Soft Speech Recognition in Children With Hearing Loss (SoftSpeech)

Hearing Loss, Sensorineural | Hearing Loss, Bilateral

United States
Centre Hospitalier Universitaire de Nice

Not yet recruiting

Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy (ALPHAGEM)

Membranous Nephropathy

France
John Mascarenhas
Roche Pharma AG; The Leukemia and Lymphoma Society

Completed

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States
Beijing Ditan Hospital

Completed

HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated

Chronic Hepatitis B

China
ANRS, Emerging Infectious Diseases
Roche Pharma AG

Unknown

A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B (PEGAN)

Chronic Hepatitis B | AgHbs Negativation

France
The Immunobiological Technology Institute (Bio-Manguinhos)...
Hospital de Clinicas de Porto Alegre

Unknown

BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C (BIP48II/III)

Chronic Hepatitis C

Brazil
Hoffmann-La Roche
Major Science and Technology Special Project of China Eleventh Five-year

Completed

A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive

Hepatitis B, Chronic

China
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (INSIGHT)

Chronic Hepatitis C

Australia, France, United Kingdom, Spain, Russian Federation, Brazil, Poland, Sweden
Hoffmann-La Roche

Completed

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

Hepatitis B, Chronic

Taiwan, United States, New Zealand, Singapore
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

Taiwan
University of Oxford
Oxford University Hospitals NHS Trust

Unknown

Self-Help Parent Training for Conduct Problems in Children

Behavioral Symptoms

United Kingdom
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction

Breast Neoplasms

China
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)

Hepatitis B, Chronic

Bulgaria
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Chronic Hepatitis B

China
Biocad

Completed

An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Hepatitis | Hepatitis C

Belarus, Russian Federation, India, Thailand
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Terminated

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Essential Thrombocythemia

France

3

Subscribe